Galectin Therapeutics Inc. (GALT)

8.95
NASDAQ : Health Technology
Prev Close 8.95
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.28 / 9.49
Avg Volume 678.80K
Exchange NASDAQ
Shares Outstanding 37.74M
Market Cap 345.71M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Galectin Therapeutics Granted Patents In China And Japan That Support NASH And Cancer Immunotherapy Clinical Development Programs

Galectin Therapeutics Granted Patents In China And Japan That Support NASH And Cancer Immunotherapy Clinical Development Programs

The broad protection of these patents opens doors to partnerships in the world's second- and third-largest pharmaceutical markets

Insiders Seeing Green With GALT At New 52-Week High

Insiders Seeing Green With GALT At New 52-Week High

In trading on Tuesday, shares of Galectin Therapeutics Inc touched a new 52-week high of $6.74/share. That's a 617.02% rise, or $5.8 per share from the 52-week low of $0.94 set back on 01/23/2017.

Galectin Therapeutics To Present Results From Phase 2b NASH-CX Trial On December 5, 2017

Galectin Therapeutics To Present Results From Phase 2b NASH-CX Trial On December 5, 2017

Company to Host Investor Conference Call at 8:30 A.M. ET

Galectin Therapeutics To Present Clinical Data At The Liver Meeting® 2017 Demonstrating The Ability Of Non-Invasive Test To Identify Clinically Significant Portal Hypertension In Patients With Compensated NASH Cirrhosis

Galectin Therapeutics To Present Clinical Data At The Liver Meeting® 2017 Demonstrating The Ability Of Non-Invasive Test To Identify Clinically Significant Portal Hypertension In Patients With Compensated NASH Cirrhosis

Research to be presented demonstrates VCTE liver stiffness measurement is a surrogate for identifying portal hypertension in patients with compensated NASH cirrhosis

Galectin Therapeutics Reports 2017 Second Quarter Financial Results And Provides Business Update

Galectin Therapeutics Reports 2017 Second Quarter Financial Results And Provides Business Update

80% of the patients enrolled have completed all 52 weeks of infusions and 99% of the doses have already been administered in the NASH Cirrhosis, NASH-CX Phase 2b Clinical Trial

Patent For Enhancing Immunotherapy In Cancer Treatment Granted To Galectin Therapeutics

Patent For Enhancing Immunotherapy In Cancer Treatment Granted To Galectin Therapeutics

Patent supports the Combination Immunotherapy trial utilizing GR-MD-02, now completed enrollment of second ascending dose cohort

Patent For Reducing Inflammatory Response Granted To Galectin Therapeutics

The patent extends the Company's coverage to areas of future clinical investigation in diseases associated with elevations in iNOS

Galectin Therapeutics Announces Important Milestones Towards Completion Of NASH CX Trial

Independent data safety monitoring board determines no safety issues in patients with NASH cirrhosis enrolled in NASH-CX trial